Annual SG&A:
$92.90M+$32.20M(+53.05%)Summary
- As of today, PCVX annual SG&A is $92.90 million, with the most recent change of +$32.20 million (+53.05%) on December 31, 2024.
- During the last 3 years, PCVX annual SG&A has risen by +$67.64 million (+267.80%).
- PCVX annual SG&A is now at all-time high.
Performance
PCVX SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly SG&A:
$32.04M-$619.00K(-1.90%)Summary
- As of today, PCVX quarterly SG&A is $32.04 million, with the most recent change of -$619.00 thousand (-1.90%) on June 30, 2025.
- Over the past year, PCVX quarterly SG&A has increased by +$10.57 million (+49.20%).
- PCVX quarterly SG&A is now -1.90% below its all-time high of $32.66 million, reached on March 31, 2025.
Performance
PCVX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM SG&A:
-$5.86B-$547.50M(-10.30%)Summary
- As of today, PCVX TTM SG&A is -$5.86 billion, with the most recent change of -$547.50 million (-10.30%) on June 30, 2025.
- Over the past year, PCVX TTM SG&A has dropped by -$5.94 billion (-7972.47%).
- PCVX TTM SG&A is now -5262.93% below its all-time high of -$109.35 million.
Performance
PCVX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Selling, General & Administrative Expenses Formula
SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development
PCVX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +53.0% | +49.2% | -7972.5% |
| 3Y3 Years | +267.8% | +240.2% | -10000.0% |
| 5Y5 Years | +987.1% | +951.9% | -10000.0% |
PCVX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +267.8% | -1.9% | +194.0% | -299.9% | at low |
| 5Y | 5-Year | at high | +987.1% | -1.9% | +568.6% | -910.3% | at low |
| All-Time | All-Time | at high | +1624.2% | -1.9% | +2334.7% | -5262.9% | at low |
PCVX Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $32.04M(-1.9%) | $116.24M(+10.0%) |
| Mar 2025 | - | $32.66M(+14.4%) | $105.68M(+13.7%) |
| Dec 2024 | $92.90M(+53.1%) | $28.55M(+24.2%) | $92.90M(+13.5%) |
| Sep 2024 | - | $22.99M(+7.1%) | $81.87M(+9.9%) |
| Jun 2024 | - | $21.47M(+8.0%) | $74.49M(+10.4%) |
| Mar 2024 | - | $19.89M(+13.5%) | $67.47M(+11.2%) |
| Dec 2023 | $60.70M(+52.5%) | $17.53M(+12.3%) | $60.70M(+10.1%) |
| Sep 2023 | - | $15.61M(+7.9%) | $55.13M(+9.3%) |
| Jun 2023 | - | $14.46M(+10.3%) | $50.42M(+11.1%) |
| Mar 2023 | - | $13.11M(+9.7%) | $45.38M(+14.0%) |
| Dec 2022 | $39.81M | $11.95M(+9.7%) | $39.81M(+15.0%) |
| Sep 2022 | - | $10.90M(+15.7%) | $34.63M(+14.5%) |
| Jun 2022 | - | $9.42M(+24.8%) | $30.25M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $7.54M(+11.4%) | $26.92M(+6.6%) |
| Dec 2021 | $25.26M(+57.7%) | $6.77M(+3.8%) | $25.26M(+8.5%) |
| Sep 2021 | - | $6.52M(+7.3%) | $23.28M(+7.5%) |
| Jun 2021 | - | $6.08M(+3.3%) | $21.65M(+16.3%) |
| Mar 2021 | - | $5.88M(+22.8%) | $18.62M(+16.3%) |
| Dec 2020 | $16.02M(+87.4%) | $4.79M(-2.2%) | $16.02M(+17.1%) |
| Sep 2020 | - | $4.90M(+60.8%) | $13.68M(+21.1%) |
| Jun 2020 | - | $3.05M(-7.2%) | $11.29M(+7.4%) |
| Mar 2020 | - | $3.28M(+33.5%) | $10.51M(+23.0%) |
| Dec 2019 | $8.55M(+58.6%) | $2.46M(-2.1%) | $8.55M(+40.3%) |
| Sep 2019 | - | $2.51M(+10.9%) | $6.09M(+70.1%) |
| Jun 2019 | - | $2.26M(+72.0%) | $3.58M(+172.0%) |
| Mar 2019 | - | $1.32M | $1.32M |
| Dec 2018 | $5.39M | - | - |
FAQ
- What is Vaxcyte, Inc. annual SG&A?
- What is the all-time high annual SG&A for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. annual SG&A year-on-year change?
- What is Vaxcyte, Inc. quarterly SG&A?
- What is the all-time high quarterly SG&A for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. quarterly SG&A year-on-year change?
- What is Vaxcyte, Inc. TTM SG&A?
- What is the all-time high TTM SG&A for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. TTM SG&A year-on-year change?
What is Vaxcyte, Inc. annual SG&A?
The current annual SG&A of PCVX is $92.90M
What is the all-time high annual SG&A for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high annual SG&A is $92.90M
What is Vaxcyte, Inc. annual SG&A year-on-year change?
Over the past year, PCVX annual SG&A has changed by +$32.20M (+53.05%)
What is Vaxcyte, Inc. quarterly SG&A?
The current quarterly SG&A of PCVX is $32.04M
What is the all-time high quarterly SG&A for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high quarterly SG&A is $32.66M
What is Vaxcyte, Inc. quarterly SG&A year-on-year change?
Over the past year, PCVX quarterly SG&A has changed by +$10.57M (+49.20%)
What is Vaxcyte, Inc. TTM SG&A?
The current TTM SG&A of PCVX is -$5.86B
What is the all-time high TTM SG&A for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high TTM SG&A is -$109.35M
What is Vaxcyte, Inc. TTM SG&A year-on-year change?
Over the past year, PCVX TTM SG&A has changed by -$5.94B (-7972.47%)